What is ImmunoCellular Therapeutics Ltd?
, a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 22.77M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.